2024 Speakers

Amanda Haas

Business Development Manager, Nucleic Acid Solutions

Agilent Technologies

Andrew Anzalone

Director, Head of Prime Editing Platform

Prime Medicine

Ankit Gupta

Senior Director, Head of Gene Editing

Affini-T Therapeutics

Apiwat Wangweerawong - Tessera, 5th Genome Editing Therapeutics 2024

Apiwat Wangweerawong

Director, Delivery Chemistry

Tessera Therapeutics

Barrett Nuttall - AstraZeneca, 5th Genome Editing Therapeutics 2024

Barrett Nuttall

Director

AstraZeneca

Britta Jones

Senior Scientist

Tune Therapeutics

Bryant Chica

Scientist II, Analytical Chemistry & Structural Biology

Editas Medicine

5th Genome Editing Therapeutics 2024

Carlo Zambonelli

Owner

Zambonelli Consulting LLC

Christina Jordan

Sr. Dir IP

Tune Therapeutics

Claire Levée

Director, Regulatory Affairs, Genetic Medicine

Regeneron Pharmaceuticals

Dave Carter

Senior Director, Head of Research

Evox Therapeutics

Eneda Hoxha

VP

ReCode Therapeutics

Jason Lehmann

Senior Product Marketing Manager

CRISPR QC

Jeffrey Cehelsky

Vice President, Development Operations

Intellia Therapeutics

Jeffrey Marshall

Analytical Director, mRNA & gRNA Platforms

Beam Therapeutics

John Murphy

Chief Scientific Officer

Arbor Biotechnologies

Jordanna Mora

Senior Director, Patient Advocacy and Centricity

Beam Therapeutics Inc.

Joseph Nabhan - Vesigen, 5th Genome Editing Therapeutics 2024

Joseph Nabhan

Chief Scientific Officer

Vesigen Therapeutics

Kiran Musunuru

Professor

University of Pennsylvania

Luca Biasco

Vice President, Translational Sciences

Nvelop Therapeutics

Marco Weinberg

SVP

ReCode Therapeutics, Inc

Mark DeWitt

Associate Director

Mammoth Biosciences

Max Sellman

Senior Product Manager, Gene Editing

Aldevron

Narin Ahmed

Vice President, Regulatory Science

Tessera Therapeutics

Omid Harandi

Chief Scientific Officer

Komo Biosciences

Priya Chockalingam

Vice President, Head of Clinical Bioanalytics & Translational Sciences

Beam Therapeutics

Ryan Leenay

Associate Vice President, Genome Editing

Eli Lilly & Co.

Ryo Takeuchi - Excision, 5th Genome Editing Therapeutics 2024

Ryo Takeuchi

Senior Director, Genome Editing

Excision BioTherapeutics Inc.

Safi Shahda - Intellia, 5th Genome Editing Therapeutics 2024

Safi Shahda

Senior Director - Medical

Intellia Therapeutics

Sam Sternberg (VIRTUAL)

Assistant Professor, Department of Biochemistry & Molecular Biophysics

Columbia University

Shane Wright - Chroma, 5th Genome Editing Therapeutics 2024

Shane Wright

Associate Scientist II

Chroma Medicine

Sheryl Bowley

Director, HSC Therapies

Editas Medicine

Simon Reed PhD

Co-Founder, CSO

Broken String Biosciences

Tetsuya Yamagata

Chief Scientific Officer

Modalis Therapeutics

TJ Cradick

Chief Technology Officer

HuidaGene Therapeutics

Tobias Brambrink

Vice President, Legal & Intellectual Property

Chroma Medicine

Vivian Choi

Head of Liver, Metabolic, Lung, Eye & Ear Disease Unit

Prime Medicine

2024 FULL EVENT GUIDE
REGISTER INTEREST FOR 2025